What is Standard BioTools' operating income?

Standard BioTools' total operating income in 2025 was -$110.25 million, based on the following breakdown: Total Gross Profit: $42.54 million Total Operating Expenses: $152.79 million

Standard BioTools (LAB) Financials

$0.85 -0.04 (-5.02%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$0.85 0.00 (-0.12%)

As of 07:27 AM Eastern

Compare

Annual Income Statements for Standard BioTools

This table shows Standard BioTools' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-53	102	108	-59	-65	-53	-59	-190	-75	-185	-75
Consolidated Net Income / (Loss)	-53	-76	-61	-59	-65	-53	-59	-190	-75	-139	-75
Net Income / (Loss) Continuing Operations	-53	102	108	-59	-65	-53	-59	-190	-75	-91	-59
Total Pre-Tax Income	-55	-80	-64	-61	-67	-54	-64	-193	-74	-90	-97
Total Operating Income	-50	-73	-58	-48	-52	-51	-67	-116	-77	-127	-110
Total Gross Profit	68	58	52	62	64	83	69	37	50	45	43
Total Revenue	115	193	186	113	117	138	131	98	106	91	85
Operating Revenue	115	193	186	113	117	138	131	98	106	91	85
Total Cost of Revenue	47	-43	-34	51	53	55	61	61	56	46	43
Operating Cost of Revenue	47	135	134	51	53	55	61	61	56	46	43
Total Operating Expenses	118	132	110	110	116	134	137	153	127	172	153
Selling, General & Admin Expense	83	93	80	80	84	98	99	102	88	103	110
Research & Development Expense	39	38	31	30	32	36	38	37	26	29	26
Restructuring Charge	-	-	-	-	-	-	-	14	14	40	17
Total Other Income / (Expense), net	-4.64	-6.99	-5.44	-13	-15	-3.07	3.80	-77	2.40	37	14
Interest Expense	5.81	5.82	5.82	14	16	3.57	3.82	4.33	4.57	3.32	0.03
Interest & Investment Income	2.33	-	-	-	-	-	0.00	2.23	5.57	20	9.18
Other Income / (Expense), net	-1.16	-1.17	0.39	0.64	1.43	0.51	7.62	-75	1.39	20	4.39
Income Tax Expense	-1.48	-4.19	-3.26	-2.41	-1.92	-1.08	-4.42	-2.83	0.45	0.54	-38
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	-	-	0.00	-48	-16
Preferred Stock Dividends Declared	-	-	-	-	-	-	-	0.00	0.00	46	0.00
Basic Earnings per Share	($1.86)	($2.62)	($1.84)	($1.49)	($0.97)	($0.74)	($0.78)	($2.43)	($0.94)	($0.52)	($0.20)
Weighted Average Basic Shares Outstanding	28.71M	29.01M	32.98M	39.65M	66.78M	72.04M	75.79M	78.31M	79.16M	353.25M	381.62M
Diluted Earnings per Share	($1.86)	($2.62)	($1.84)	($1.49)	($0.97)	($0.74)	($0.78)	($2.43)	($0.94)	($0.52)	($0.20)
Weighted Average Diluted Shares Outstanding	28.71M	29.01M	32.98M	39.65M	66.78M	72.04M	75.79M	78.31M	79.16M	353.25M	381.62M
Weighted Average Basic & Diluted Shares Outstanding	28.71M	29.01M	32.98M	39.65M	66.78M	72.04M	77.20M	79.06M	290.12M	378.99M	390.07M

This table shows Standard BioTools' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-21	-20	-78	-46	-27	-34	-26	-33	-35	19	127
Consolidated Net Income / (Loss)	-21	-20	-32	-46	-27	-34	-26	-33	-35	19	127
Net Income / (Loss) Continuing Operations	-21	-20	-32	-25	-22	-11	-23	-18	-32	17	-15
Total Pre-Tax Income	-21	-20	-32	-25	-22	-11	-23	-18	-33	-19	-15
Total Operating Income	-21	-21	-60	-30	-27	-10	-27	-26	-33	-19	-12
Total Gross Profit	11	13	24	10	12	-1.81	11	11	9.48	2.69	11
Total Revenue	25	28	46	22	22	0.89	20	22	20	3.22	21
Operating Revenue	25	28	46	22	22	0.89	20	22	20	3.22	21
Total Cost of Revenue	14	15	21	12	9.96	2.70	9.17	11	10	0.53	9.84
Operating Cost of Revenue	14	15	21	12	9.96	2.70	9.17	11	10	0.53	9.84
Total Operating Expenses	32	35	84	41	39	8.54	38	36	42	21	24
Selling, General & Admin Expense	22	21	47	25	24	6.79	30	28	27	16	19
Research & Development Expense	6.37	6.97	16	7.24	6.94	-1.33	5.44	6.22	6.36	2.08	2.12
Restructuring Charge	3.66	6.48	21	8.53	7.42	3.08	2.76	2.00	9.47	2.80	3.08
Total Other Income / (Expense), net	0.23	1.45	28	4.86	4.90	-0.82	3.48	7.42	0.04	-0.69	-2.12
Interest & Investment Income	0.34	4.92	6.21	5.30	4.79	3.90	2.91	2.46	2.14	1.66	3.51
Other Income / (Expense), net	-0.12	1.10	23	0.41	0.96	-4.14	0.57	4.96	-2.09	-2.35	-5.63
Income Tax Expense	0.05	-0.16	0.13	0.04	0.12	0.26	-0.12	-0.61	-1.22	-36	0.01
Net Income / (Loss) Discontinued Operations	-	-	-	-20	-5.02	-	-2.66	-16	-3.00	-	142
Basic Earnings per Share	($0.27)	($0.24)	($0.27)	($0.12)	($0.07)	($0.06)	($0.07)	($0.09)	($0.09)	$0.05	$0.33
Weighted Average Basic Shares Outstanding	79.15M	79.16M	294.13M	372.33M	371.54M	353.25M	378.23M	380.50M	382.63M	381.62M	388.20M
Diluted Earnings per Share	($0.27)	($0.24)	($0.27)	($0.12)	($0.07)	($0.06)	($0.07)	($0.09)	($0.09)	$0.05	$0.33
Weighted Average Diluted Shares Outstanding	79.15M	79.16M	294.13M	372.33M	371.54M	353.25M	378.23M	380.50M	382.63M	381.62M	388.20M

This table details how cash moves in and out of Standard BioTools' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-4.60	5.93	23	37	-72	46	-40	53	-30	116	-46
Net Cash From Operating Activities	-35	-39	-24	-25	-35	-15	-44	-89	-43	-143	-74
Net Cash From Continuing Operating Activities	-35	-39	-24	-25	-35	-15	-44	-89	-43	-143	-74
Net Income / (Loss) Continuing Operations	-53	-76	-61	-59	-65	-53	-59	-190	-75	-139	-75
Consolidated Net Income / (Loss)	-53	-76	-61	-59	-65	-53	-59	-190	-75	-139	-75
Depreciation Expense	4.92	6.74	7.41	5.37	4.61	4.01	3.65	3.50	3.98	13	9.26
Amortization Expense	11	11	11	20	13	14	13	11	9.94	-3.09	-0.93
Non-Cash Adjustments To Reconcile Net Income	11	14	11	12	26	16	18	101	15	8.31	33
Changes in Operating Assets and Liabilities, net	-8.13	4.96	6.24	-3.39	-13	2.84	-19	-14	2.73	-22	-41
Net Cash From Investing Activities	26	45	18	4.72	-39	40	-12	-88	20	363	27
Net Cash From Continuing Investing Activities	26	45	18	4.72	-39	40	-12	-88	20	363	27
Purchase of Property, Plant & Equipment	-3.98	-5.07	-1.57	-0.37	-2.53	-13	-13	-3.83	-2.83	-8.36	-8.30
Acquisitions	-6.67	0.00	-0.05	0.00	0.00	-5.15	-	0.00	0.00	-1.39	0.00
Purchase of Investments	-67	-39	-6.28	-1.45	-62	0.00	0.00	-137	-95	-256	-138
Sale and/or Maturity of Investments	103	89	26	6.54	26	37	0.00	53	118	349	179
Other Investing Activities, net	-	-	-	0.00	0.00	21	1.32	0.00	0.00	280	-5.00
Net Cash From Financing Activities	5.34	0.12	29	58	2.79	21	16	231	-6.81	-103	0.57
Net Cash From Continuing Financing Activities	5.34	0.12	29	58	2.79	21	16	231	-6.81	-103	0.57
Repayment of Debt	-	0.00	0.00	0.00	-52	0.00	-0.50	-6.84	-2.08	-64	0.00
Repurchase of Common Equity	-	-	0.00	-2.86	-1.89	-0.68	-0.08	-13	-5.41	-40	0.00
Issuance of Common Equity	0.00	0.00	29	61	1.08	22	1.49	0.82	0.72	0.92	0.52
Other Financing Activities, net	5.34	0.12	-0.02	-0.15	0.43	-0.01	-1.79	-0.11	-0.04	0.69	0.05
Effect of Exchange Rate Changes	-0.95	-0.15	-	-	0.06	0.39	-0.02	-0.40	0.03	-0.79	0.84
Cash Interest Paid	5.54	5.53	5.53	5.53	3.54	3.09	3.15	3.49	3.82	3.09	0.02
Cash Income Taxes Paid	0.19	0.36	0.25	0.32	0.21	0.52	2.09	0.31	0.80	0.61	-0.07

This table details how cash moves in and out of Standard BioTools' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-63	-28	236	-17	-59	-43	-15	7.73	-29	-8.71	145
Net Cash From Operating Activities	-11	-14	-62	-39	-28	-14	-30	-21	-22	-1.19	-47
Net Cash From Continuing Operating Activities	-11	-14	-62	-39	-28	-14	-30	-21	-22	-1.19	-47
Net Income / (Loss) Continuing Operations	-21	-20	-32	-46	-27	-34	-26	-33	-35	19	127
Consolidated Net Income / (Loss)	-21	-20	-32	-46	-27	-34	-26	-33	-35	19	127
Depreciation Expense	1.19	1.11	3.09	3.14	3.15	3.14	3.27	3.18	1.52	1.29	1.41
Amortization Expense	2.63	1.86	-0.55	-1.17	-1.05	-0.32	0.06	0.09	-0.61	-0.46	-0.63
Non-Cash Adjustments To Reconcile Net Income	6.60	1.23	-11	8.15	10	3.40	9.53	5.29	14	3.01	-159
Changes in Operating Assets and Liabilities, net	-0.83	1.52	-22	-3.45	-13	14	-17	4.23	-2.15	-24	-15
Net Cash From Investing Activities	-50	-13	318	50	-31	26	15	28	-6.68	-8.04	191
Net Cash From Continuing Investing Activities	-50	-13	318	50	-31	26	15	28	-6.68	-8.04	191
Purchase of Property, Plant & Equipment	-0.91	-0.08	-0.78	-1.94	-2.26	-3.38	-5.05	-1.89	-0.89	-0.48	-0.57
Purchase of Investments	-49	-39	-73	-75	-79	-30	-32	-19	-60	-28	-187
Divestitures	-	-	-	-	-	-	0.00	-	-	-	363
Sale and/or Maturity of Investments	-	26	112	127	50	60	52	48	54	25	15
Net Cash From Financing Activities	-1.16	-1.00	-20	-28	-0.00	-55	-0.05	0.11	-0.11	0.62	-0.04
Net Cash From Continuing Financing Activities	-1.16	-1.00	-20	-28	-0.00	-55	-0.05	0.11	-0.11	0.62	-0.04
Repayment of Debt	-0.83	-1.25	-8.74	-	-	-55	0.00	-	-	-	0.00
Repurchase of Common Equity	-0.40	-0.17	-11	-29	-	-	0.00	-	-	-	0.00
Issuance of Common Equity	-	0.40	-	-	-	0.49	0.00	-	-	0.22	0.00
Other Financing Activities, net	0.07	0.02	0.06	0.65	-0.00	-0.01	-0.05	-0.20	-0.11	0.41	-0.04
Effect of Exchange Rate Changes	-0.15	0.23	-0.02	-0.09	-0.41	-0.27	0.36	0.79	-0.20	-0.10	0.12
Cash Interest Paid	0.25	1.65	0.19	1.45	0.00	1.44	0.00	0.01	0.01	-	0.00
Cash Income Taxes Paid	0.12	0.17	0.24	0.11	0.06	0.20	-0.20	-0.18	-0.07	-0.02	-0.01

This table presents Standard BioTools' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	370	306	287	304	265	325	275	390	323	612	568
Total Current Assets	144	97	95	127	96	118	72	209	158	376	454
Cash & Equivalents	29	35	58	95	22	69	28	81	52	167	121
Short-Term Investments	66	24	5.08	0.00	37	-	0.00	84	63	126	67
Accounts Receivable	25	15	15	17	19	25	18	17	20	15	13
Inventories, net	18	20	15	13	14	20	21	21	21	21	20
Prepaid Expenses	5.74	2.52	1.53	2.05	4.59	4.03	4.47	4.28	3.13	4.56	4.87
Other Current Assets	-	-	-	-	-	-	-	-	-	-	0.00
Other Current Nonoperating Assets	-	-	-	-	-	-	-	-	-	43	228
Plant, Property, & Equipment, net	15	17	12	8.83	8.06	18	28	26	24	23	19
Total Noncurrent Assets	211	193	180	168	161	190	175	156	141	214	94
Long-Term Investments	6.49	-	-	-	-	-	-	-	-	0.00	26
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	-	-	0.14	39
Other Noncurrent Operating Assets	9.10	9.29	7.54	6.21	10	43	41	37	33	30	30
Total Liabilities & Shareholders' Equity	370	306	287	304	265	325	275	390	323	612	568
Total Liabilities	255	253	256	232	111	186	181	161	160	141	143
Total Current Liabilities	30	30	33	38	33	54	50	43	109	66	108
Accounts Payable	6.09	3.97	4.21	4.03	5.15	9.22	11	7.91	9.24	5.05	5.41
Accrued Expenses	11	12	8.49	7.62	8.87	12	8.67	6.18	21	21	30
Current Deferred Revenue	9.42	9.16	10	11	12	16	15	14	15	14	42
Other Current Liabilities	-	-	-	0.00	1.83	2.97	3.05	3.68	4.32	4.81	5.49
Other Current Nonoperating Liabilities	-	-	-	-	-	-	-	-	-	21	26
Total Noncurrent Liabilities	225	224	223	194	78	131	131	117	51	75	35
Long-Term Debt	195	195	195	172	54	54	64	63	3.98	0.30	0.30
Noncurrent Deferred Revenue	4.40	4.32	4.96	6.33	8.17	7.99	5.97	3.82	3.52	33	3.50
Noncurrent Deferred & Payable Income Tax Liabilities	24	21	17	14	11	8.70	4.33	1.06	0.84	1.08	0.81
Other Noncurrent Operating Liabilities	2.40	3.26	5.83	1.85	4.90	61	57	49	42	34	31
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	115	53	31	72	154	139	95	-81	-148	472	424
Total Preferred & Common Equity	115	53	31	72	154	139	95	-81	-148	472	424
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	115	53	31	72	154	139	95	-81	-148	472	424
Common Stock	480	493	532	632	778	816	832	847	861	1,703	1,733
Retained Earnings	-363	-439	-500	-559	-624	-677	-736	-926	-1,001	-1,186	-1,261
Treasury Stock	-	-	-	-	-	-	0.00	-0.56	-5.98	-46	-46
Accumulated Other Comprehensive Income / (Loss)	-1.14	-0.76	-0.57	-0.69	-0.58	0.11	-0.91	-1.90	-2.22	1.23	-1.49

This table presents Standard BioTools' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	415	372	356	339	709	682	580	557	540	639
Total Current Assets	229	195	183	171	480	454	344	506	472	521
Cash & Equivalents	60	114	142	80	270	211	151	159	129	266
Short-Term Investments	125	41	0.00	49	125	156	107	78	65	189
Accounts Receivable	17	15	15	17	32	35	35	15	14	17
Inventories, net	22	23	22	22	43	43	42	24	25	19
Prepaid Expenses	4.61	3.37	3.57	3.40	10	9.32	8.35	7.08	7.91	6.05
Other Current Assets	-	-	-	-	-	-	-	-	-	25
Other Current Nonoperating Assets	-	-	-	-	-	-	-	223	231	0.00
Plant, Property, & Equipment, net	27	25	25	25	43	42	44	23	21	17
Total Noncurrent Assets	159	152	148	144	186	186	192	28	46	101
Long-Term Investments	-	-	-	-	-	-	-	-	19	71
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	-	-	0.27
Other Noncurrent Operating Assets	38	36	35	34	56	56	52	28	27	29
Total Liabilities & Shareholders' Equity	415	372	356	339	709	682	580	557	540	639
Total Liabilities	166	158	158	160	198	192	125	132	140	78
Total Current Liabilities	46	44	47	52	124	121	56	98	108	42
Accounts Payable	9.31	6.11	6.09	7.33	13	11	12	7.33	6.62	8.01
Accrued Expenses	6.91	6.88	7.18	10	32	32	22	24	31	16
Current Deferred Revenue	15	15	15	15	19	17	16	43	43	13
Other Current Liabilities	3.52	3.76	3.91	3.98	5.85	6.12	6.33	5.09	5.11	5.54
Other Current Nonoperating Liabilities	-	-	-	-	-	-	-	18	22	0.00
Total Noncurrent Liabilities	120	114	111	108	75	72	69	34	32	36
Long-Term Debt	64	62	61	60	0.30	0.30	0.30	0.30	0.30	0.30
Noncurrent Deferred Revenue	4.43	3.83	3.79	3.47	33	33	33	2.79	2.37	3.01
Noncurrent Deferred & Payable Income Tax Liabilities	0.62	1.05	1.05	1.02	0.84	0.84	1.03	1.08	1.14	0.82
Other Noncurrent Operating Liabilities	51	47	46	44	40	38	35	30	28	32
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-63	-97	-113	-132	510	489	455	425	400	561
Total Preferred & Common Equity	-63	-97	-113	-132	510	489	455	425	400	561
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-63	-97	-113	-132	510	489	455	425	400	561
Common Stock	845	850	854	857	1,683	1,689	1,712	1,718	1,726	1,742
Retained Earnings	-905	-943	-960	-981	-1,125	-1,152	-1,212	-1,245	-1,280	-1,133
Treasury Stock	-	-3.03	-5.40	-5.80	-46	-46	-46	-46	-46	-46
Accumulated Other Comprehensive Income / (Loss)	-2.61	-1.33	-1.55	-1.95	-1.50	-1.41	1.17	-1.93	-0.48	-0.51

This table displays calculated financial ratios and metrics derived from Standard BioTools' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	28,792,350.00	29,118,140.00	38,647,687.00	39,322,608.00	69,564,909.00	74,119,005.00	-	-	-	-	384,565,414.00
DEI Adjusted Shares Outstanding	28,792,350.00	29,118,140.00	38,647,687.00	39,322,608.00	69,564,909.00	74,119,005.00	-	-	-	-	384,565,414.00
DEI Earnings Per Adjusted Shares Outstanding	-1.85	3.50	2.80	-1.50	-0.93	-0.72	-	-	-	-	-0.19
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.50%	68.64%	-3.68%	-39.38%	3.79%	17.83%	-5.47%	-24.99%	8.57%	64.03%	-6.24%
EBITDA Growth	9.36%	-59.51%	30.39%	42.23%	-46.97%	3.43%	-36.20%	-304.36%	65.27%	-137.83%	0.34%
EBIT Growth	2.62%	-44.91%	22.03%	18.02%	-6.06%	-0.24%	-18.42%	-218.90%	60.59%	-106.35%	1.33%
NOPAT Growth	3.24%	-45.93%	20.26%	17.47%	-7.63%	1.55%	-32.18%	-72.26%	34.08%	-128.77%	13.52%
Net Income Growth	-0.92%	-42.52%	20.33%	2.51%	-9.79%	18.17%	-11.73%	-220.91%	60.73%	-86.03%	46.07%
EPS Growth	2.11%	-40.86%	29.77%	19.02%	34.90%	23.71%	-5.41%	-211.54%	61.32%	44.68%	61.54%
Operating Cash Flow Growth	-53.53%	-12.68%	38.43%	-4.58%	-39.72%	56.21%	-185.79%	-102.83%	51.56%	-231.40%	48.18%
Free Cash Flow Firm Growth	82.49%	20.59%	52.52%	-28.52%	-86.67%	67.82%	-410.55%	-22.44%	49.97%	-419.87%	-349.45%
Invested Capital Growth	2.48%	-9.30%	-13.62%	-8.75%	0.01%	-16.16%	9.97%	-6.05%	-13.25%	60.21%	143.43%
Revenue Q/Q Growth	-2.36%	75.73%	0.00%	0.00%	288.80%	9.66%	-4.63%	-10.30%	1.11%	0.00%	-48.73%
EBITDA Q/Q Growth	-12.22%	-6.07%	-295.75%	-202.55%	-2.64%	-26.80%	13.42%	-73.03%	-2.61%	0.00%	28.78%
EBIT Q/Q Growth	-7.50%	-6.25%	0.00%	0.00%	4.32%	-17.38%	10.44%	-61.57%	-0.94%	0.00%	28.12%
NOPAT Q/Q Growth	-8.34%	-5.79%	0.00%	0.00%	3.60%	-17.83%	7.72%	-9.26%	-0.36%	0.00%	26.35%
Net Income Q/Q Growth	-3.77%	-6.77%	0.00%	0.00%	3.13%	-11.20%	12.67%	-6.39%	1.41%	0.00%	41.60%
EPS Q/Q Growth	-3.33%	-6.50%	0.00%	0.00%	17.80%	-17.46%	14.29%	-5.65%	1.05%	0.00%	35.48%
Operating Cash Flow Q/Q Growth	-2.60%	-19.28%	32.10%	-5.43%	-16.09%	10.38%	-8.01%	-15.78%	10.58%	0.00%	14.76%
Free Cash Flow Firm Q/Q Growth	-13.63%	7.30%	-176.66%	-222.07%	-15.59%	18.69%	-15.85%	-6.74%	10.09%	0.00%	-209.41%
Invested Capital Q/Q Growth	1.20%	-1.49%	-5.13%	-4.59%	-0.60%	-6.73%	2.33%	0.65%	-3.00%	0.00%	137.31%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	59.35%	30.21%	27.90%	54.57%	54.83%	60.32%	53.13%	37.83%	47.44%	48.31%	49.86%
EBITDA Margin	-30.68%	-29.02%	-20.97%	-19.99%	-28.30%	-23.20%	-33.42%	-180.17%	-57.64%	-83.57%	-114.29%
Operating Margin	-43.72%	-37.83%	-31.32%	-42.64%	-44.22%	-36.94%	-51.66%	-118.64%	-72.03%	-100.46%	-129.20%
EBIT Margin	-44.73%	-38.44%	-31.11%	-42.07%	-42.99%	-36.58%	-45.82%	-194.82%	-70.73%	-88.97%	-124.05%
Profit (Net Income) Margin	-46.48%	-39.28%	-32.49%	-52.24%	-55.26%	-38.38%	-45.36%	-194.08%	-70.21%	-79.62%	-87.77%
Tax Burden Percent	97.31%	94.77%	94.88%	96.08%	97.13%	98.00%	93.05%	98.53%	100.61%	100.41%	77.45%
Interest Burden Percent	106.78%	107.83%	110.05%	129.23%	132.34%	107.07%	106.39%	101.10%	98.66%	89.12%	91.35%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-17.08%	-25.82%	-23.23%	-21.63%	-24.39%	-26.12%	-36.05%	-61.14%	-44.55%	-84.32%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-42.04%	-47.46%	-37.93%	-45.86%	-103.74%	154.84%	-120.97%	311.97%	-16.92%	-74.88%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-23.11%	-64.57%	-120.62%	-92.91%	-33.02%	-10.11%	-14.65%	-56.07%	6.56%	40.57%	0.00%
Return on Equity (ROE)	-40.19%	-90.39%	-143.84%	-114.53%	-57.41%	-36.23%	-50.71%	-117.21%	-37.99%	-43.75%	-16.72%
Cash Return on Invested Capital (CROIC)	-19.53%	-16.07%	-8.60%	-12.48%	-24.40%	-8.54%	-45.55%	-54.90%	-30.36%	-130.59%	-1,233.82%
Operating Return on Assets (OROA)	-13.20%	-21.98%	-19.53%	-16.08%	-17.73%	-17.14%	-19.95%	-57.35%	-21.09%	-33.18%	-17.94%
Return on Assets (ROA)	-13.71%	-22.47%	-20.39%	-19.97%	-22.80%	-17.99%	-19.75%	-57.13%	-20.93%	-29.70%	-12.69%
Return on Common Equity (ROCE)	-40.19%	-90.39%	-143.84%	-114.53%	-57.41%	-36.23%	-50.71%	-4.74%	22.19%	-22.30%	-16.72%
Return on Equity Simple (ROE_SIMPLE)	-46.40%	-142.74%	-195.68%	-81.83%	-42.18%	-38.13%	-62.62%	233.34%	50.43%	-29.44%	0.00%
Net Operating Profit after Tax (NOPAT)	-35	-51	-41	-34	-36	-36	-47	-81	-54	-123	-77
NOPAT Margin	-30.61%	-26.48%	-21.92%	-29.85%	-30.95%	-25.86%	-36.16%	-83.05%	-50.42%	-70.32%	-90.44%
Net Nonoperating Expense Percent (NNEP)	24.96%	21.64%	14.71%	24.24%	79.35%	-180.96%	84.92%	-373.11%	-27.63%	-9.43%	0.50%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	490.76%	63.43%	-25.99%	-18.18%
Cost of Revenue to Revenue	40.65%	-22.23%	-18.48%	45.43%	45.17%	39.68%	46.87%	62.17%	52.56%	51.69%	50.14%
SG&A Expenses to Revenue	72.32%	48.18%	42.67%	70.63%	72.05%	70.87%	75.73%	104.43%	82.32%	89.78%	128.75%
R&D to Revenue	34.23%	19.86%	16.54%	26.58%	26.99%	26.39%	29.06%	38.17%	24.40%	35.78%	30.45%
Operating Expenses to Revenue	103.07%	68.04%	59.22%	97.21%	99.04%	97.26%	104.79%	156.47%	119.48%	148.77%	179.06%
Earnings before Interest and Taxes (EBIT)	-51	-74	-58	-48	-50	-51	-60	-191	-75	-155	-106
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-35	-56	-39	-23	-33	-32	-44	-176	-61	-146	-98
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.71	3.98	7.36	4.70	1.58	3.20	3.17	0.00	0.00	1.38	1.16
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	73.27	0.00	0.00	0.00	0.00	1.97	1.16
Price to Revenue (P/Rev)	2.71	1.10	1.22	3.00	2.06	3.22	2.30	0.95	1.65	3.73	5.77
Price to Earnings (P/E)	0.00	2.08	2.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	48.13%	47.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.94	1.84	2.21	2.79	1.59	3.45	2.50	2.35	3.89	2.00	32.70
Enterprise Value to Revenue (EV/Rev)	3.53	1.80	1.93	3.68	2.02	3.12	2.62	3.09	4.09	2.06	3.27
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.69	3.66	6.31	2.39	0.35	0.39	0.75	0.28	0.39	0.00	0.00
Long-Term Debt to Equity	1.69	3.66	6.31	2.39	0.35	0.39	0.68	0.27	0.02	0.00	0.00
Financial Leverage	0.55	1.36	3.18	2.03	0.32	-0.07	0.12	-0.18	-0.39	-0.54	-1.01
Leverage Ratio	2.93	4.02	7.05	5.74	2.52	2.01	2.57	2.05	1.82	1.47	1.32
Compound Leverage Factor	3.13	4.34	7.76	7.41	3.33	2.16	2.73	2.07	1.79	1.31	1.20
Debt to Total Capital	62.88%	78.55%	86.32%	70.47%	25.95%	28.06%	42.89%	22.02%	28.01%	0.06%	0.07%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.13%	0.71%	26.26%	0.00%	0.00%
Long-Term Debt to Total Capital	62.88%	78.55%	86.32%	70.47%	25.95%	28.06%	38.76%	21.31%	1.76%	0.06%	0.07%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	105.62%	137.29%	0.00%	0.00%
Common Equity to Total Capital	37.12%	21.45%	13.68%	29.53%	74.05%	71.94%	57.11%	-27.65%	-65.30%	99.94%	99.93%
Debt to EBITDA	-5.53	-3.47	-5.00	-7.62	-1.62	-1.69	-1.63	-0.37	-1.04	0.00	0.00
Net Debt to EBITDA	-2.65	-2.41	-3.38	-3.40	0.15	0.45	-0.98	0.57	0.84	2.01	2.18
Long-Term Debt to EBITDA	-5.53	-3.47	-5.00	-7.62	-1.62	-1.69	-1.47	-0.36	-0.07	0.00	0.00
Debt to NOPAT	-5.54	-3.81	-4.78	-5.10	-1.48	-1.52	-1.50	-0.80	-1.18	0.00	0.00
Net Debt to NOPAT	-2.65	-2.65	-3.23	-2.27	0.13	0.40	-0.90	1.24	0.96	2.39	2.76
Long-Term Debt to NOPAT	-5.54	-3.81	-4.78	-5.10	-1.48	-1.52	-1.36	-0.77	-0.07	0.00	0.00
Altman Z-Score	-0.42	-1.41	-1.67	-1.49	-1.89	-1.33	-2.89	-3.83	-3.94	0.12	-0.78
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	95.95%	158.40%	49.02%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.79	3.28	2.83	3.38	2.93	2.17	1.45	4.81	1.45	5.70	4.19
Quick Ratio	4.00	2.51	2.34	2.98	2.36	1.73	0.94	4.21	1.23	4.95	1.86
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-40	-32	-15	-19	-36	-12	-60	-73	-37	-190	-105
Operating Cash Flow to CapEx	-872.25%	-772.71%	-1,538.83%	-6,774.46%	-1,391.15%	-121.23%	-332.18%	-2,336.47%	-1,529.04%	-1,716.98%	-895.38%
Free Cash Flow to Firm to Interest Expense	-6.91	-5.48	-2.60	-1.40	-2.23	-3.27	-15.61	-16.87	-8.00	-57.30	-4,053.09
Operating Cash Flow to Interest Expense	-5.98	-6.72	-4.14	-1.81	-2.16	-4.32	-11.53	-20.64	-9.48	-43.26	-2,859.35
Operating Cash Flow Less CapEx to Interest Expense	-6.67	-7.60	-4.41	-1.84	-2.32	-7.88	-14.99	-21.52	-10.10	-45.78	-3,178.69
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.57	0.63	0.38	0.41	0.47	0.44	0.29	0.30	0.37	0.14
Accounts Receivable Turnover	4.80	9.66	12.57	7.13	6.58	6.22	5.97	5.50	5.76	6.55	6.06
Inventory Turnover	2.75	0.00	0.00	3.65	3.94	3.27	3.02	2.88	2.66	2.94	2.10
Fixed Asset Turnover	7.87	12.17	12.93	10.69	13.89	10.80	5.73	3.65	4.27	5.23	4.06
Accounts Payable Turnover	7.76	0.00	0.00	12.46	11.54	7.63	6.18	6.58	6.52	8.38	8.18
Days Sales Outstanding (DSO)	76.11	37.80	29.05	51.21	55.46	58.66	61.14	66.33	63.40	55.73	60.25
Days Inventory Outstanding (DIO)	132.74	0.00	0.00	99.90	92.65	111.77	120.80	126.76	137.16	124.01	173.70
Days Payable Outstanding (DPO)	47.02	0.00	0.00	29.30	31.63	47.85	59.10	55.49	56.00	43.55	44.60
Cash Conversion Cycle (CCC)	161.83	37.80	29.05	121.82	116.48	122.59	122.83	137.60	144.56	136.19	189.36
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	208	189	163	149	149	125	137	129	112	179	8.54
Invested Capital Turnover	0.56	0.97	1.06	0.72	0.79	1.01	1.00	0.74	0.88	1.20	-15.34
Increase / (Decrease) in Invested Capital	5.04	-19	-26	-14	0.02	-24	12	-8.30	-17	67	28
Enterprise Value (EV)	404	348	360	416	237	430	342	303	435	359	279
Market Capitalization	311	212	228	339	242	445	300	93	175	651	492
Book Value per Share	$3.99	$1.83	$0.80	$1.83	$2.21	$1.88	$1.24	($1.03)	($1.86)	$1.27	$1.10
Tangible Book Value per Share	($2.79)	($4.49)	($3.67)	($2.27)	$0.05	($0.10)	($0.52)	($2.53)	($3.22)	$0.89	$1.10
Total Capital	310	248	226	244	207	193	166	295	227	472	425
Total Debt	195	195	195	172	54	54	71	65	64	0.30	0.30
Total Long-Term Debt	195	195	195	172	54	54	64	63	3.98	0.30	0.30
Net Debt	93	136	132	77	-4.82	-14	43	-101	-51	-293	-213
Capital Expenditures (CapEx)	3.98	5.07	1.57	0.37	2.53	13	13	3.83	2.83	8.36	8.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	19	7.74	-1.81	-5.88	4.64	-5.11	0.89	1.67	-6.48	17	158
Debt-free Net Working Capital (DFNWC)	114	67	61	90	63	63	29	167	108	310	346
Net Working Capital (NWC)	114	67	61	90	63	63	22	165	49	310	346
Net Nonoperating Expense (NNE)	18	25	20	25	29	17	12	109	21	16	-2.28
Net Nonoperating Obligations (NNO)	93	136	132	77	-4.82	-14	43	-101	-51	-293	-416
Total Depreciation and Amortization (D&A)	16	18	19	25	17	18	16	14	14	9.43	8.33
Debt-free, Cash-free Net Working Capital to Revenue	16.60%	4.00%	-0.97%	-5.20%	3.95%	-3.70%	0.68%	1.71%	-6.09%	9.81%	185.61%
Debt-free Net Working Capital to Revenue	99.39%	34.72%	32.91%	79.25%	53.97%	45.90%	22.47%	170.96%	101.95%	177.71%	405.43%
Net Working Capital to Revenue	99.39%	34.72%	32.91%	79.25%	53.97%	45.90%	17.23%	168.84%	45.97%	177.71%	405.43%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.86)	($2.62)	($1.84)	($1.49)	($0.97)	($0.74)	($0.78)	($2.43)	($0.94)	($0.52)	($0.20)
Adjusted Weighted Average Basic Shares Outstanding	28.84M	29.21M	38.81M	68.99M	70.45M	74.55M	75.79M	78.31M	79.16M	353.25M	381.62M
Adjusted Diluted Earnings per Share	($1.86)	($2.62)	($1.84)	($1.49)	($0.97)	($0.74)	($0.78)	($2.43)	($0.94)	($0.52)	($0.20)
Adjusted Weighted Average Diluted Shares Outstanding	28.84M	29.21M	38.81M	68.99M	70.45M	74.55M	75.79M	78.31M	79.16M	353.25M	381.62M
Adjusted Basic & Diluted Earnings per Share	($1.86)	($2.62)	($1.84)	($1.49)	($0.97)	($0.74)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.71M	29.01M	32.98M	39.65M	66.78M	72.04M	77.20M	79.06M	290.12M	378.99M	390.07M
Normalized Net Operating Profit after Tax (NOPAT)	-35	-51	-41	-34	-36	-36	-47	-72	-44	-94	-65
Normalized NOPAT Margin	-30.61%	-26.48%	-21.92%	-29.85%	-30.95%	-25.86%	-36.16%	-73.34%	-41.50%	-54.08%	-76.54%
Pre Tax Income Margin	-47.76%	-41.45%	-34.24%	-54.37%	-56.89%	-39.16%	-48.75%	-196.97%	-69.78%	-79.29%	-113.33%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.83	-12.78	-9.95	-3.42	-3.09	-14.15	-15.65	-44.06	-16.47	-46.80	-4,071.35
NOPAT to Interest Expense	-6.04	-8.80	-7.01	-2.43	-2.23	-10.00	-12.35	-18.78	-11.74	-36.99	-2,968.24
EBIT Less CapEx to Interest Expense	-9.52	-13.65	-10.22	-3.45	-3.25	-17.71	-19.12	-44.94	-17.09	-49.32	-4,390.69
NOPAT Less CapEx to Interest Expense	-6.73	-9.67	-7.28	-2.45	-2.38	-13.56	-15.82	-19.66	-12.36	-39.51	-3,287.59
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-4.85%	-2.91%	-1.29%	-0.13%	-6.90%	-7.25%	-29.15%	0.00%

This table displays calculated financial ratios and metrics derived from Standard BioTools' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	290,117,930.00	-	-	372,258,798.00	378,986,362.00	379,822,268.00	381,995,102.00	384,565,414.00	390,071,506.00
DEI Adjusted Shares Outstanding	-	-	290,117,930.00	-	-	372,258,798.00	378,986,362.00	379,822,268.00	381,995,102.00	384,565,414.00	390,071,506.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-0.27	-	-	-0.09	-0.07	-0.09	-0.09	0.05	0.33
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.09%	4.32%	81.30%	34.48%	77.27%	-96.84%	-55.60%	-3.25%	-11.47%	262.02%	4.57%
EBITDA Growth	30.90%	78.23%	-163.54%	-275.53%	-64.05%	32.65%	33.45%	37.33%	-44.31%	-72.86%	24.80%
EBIT Growth	26.82%	75.23%	-123.41%	-195.04%	-44.51%	28.59%	29.03%	30.54%	-36.08%	-44.92%	31.35%
NOPAT Growth	27.06%	-1.30%	-262.70%	-189.52%	-49.81%	51.64%	55.19%	15.08%	-23.37%	-80.26%	53.67%
Net Income Growth	28.64%	5.13%	-90.92%	-168.30%	-28.29%	-72.29%	19.04%	26.81%	-28.77%	156.59%	588.10%
EPS Growth	27.03%	4.00%	-28.57%	45.45%	74.07%	75.00%	74.07%	25.00%	-28.57%	183.33%	571.43%
Operating Cash Flow Growth	53.63%	26.69%	-636.31%	0.00%	-144.21%	0.01%	51.53%	47.07%	20.33%	91.54%	-53.87%
Free Cash Flow Firm Growth	85.76%	132.46%	287.15%	-1,346.95%	-4,079.08%	5,805.74%	-361.46%	339.41%	318.12%	-133.21%	171.02%
Invested Capital Growth	-9.98%	-13.25%	0.00%	41.24%	54.60%	-117.59%	0.00%	-110.17%	-112.85%	143.43%	-82.27%
Revenue Q/Q Growth	-8.31%	11.12%	61.56%	0.00%	20.87%	-95.97%	2,172.13%	-46.66%	-10.16%	-83.52%	556.30%
EBITDA Q/Q Growth	-30.94%	0.86%	-100.16%	0.00%	42.80%	50.66%	-97.80%	32.20%	-95.31%	40.90%	13.96%
EBIT Q/Q Growth	-25.34%	4.70%	-83.38%	0.00%	38.61%	43.73%	-82.27%	28.74%	-68.95%	40.07%	13.66%
NOPAT Q/Q Growth	-21.34%	-1.01%	-181.41%	0.00%	37.22%	61.26%	-160.76%	22.06%	-28.18%	43.40%	32.98%
Net Income Q/Q Growth	-23.22%	5.82%	-62.61%	0.00%	41.08%	-26.48%	23.59%	-28.53%	-3.67%	155.59%	558.96%
EPS Q/Q Growth	-22.73%	11.11%	-12.50%	0.00%	41.67%	14.29%	-16.67%	-28.57%	0.00%	155.56%	560.00%
Operating Cash Flow Q/Q Growth	-22.33%	-23.21%	-344.32%	0.00%	0.00%	49.55%	-115.40%	31.75%	-7.42%	94.64%	-3,815.71%
Free Cash Flow Firm Q/Q Growth	65.39%	203.26%	3,821.60%	0.00%	0.05%	252.20%	-273.62%	177.30%	4.74%	-123.17%	471.32%
Invested Capital Q/Q Growth	-4.58%	-3.00%	-100.00%	0.00%	4.45%	-111.03%	1,100.93%	-108.82%	-31.90%	137.31%	308.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	43.97%	47.58%	53.11%	40.07%	51.73%	-202.81%	54.64%	48.84%	48.51%	83.49%	53.48%
EBITDA Margin	-68.87%	-61.45%	-76.13%	-134.68%	-63.74%	-1,310.67%	-114.10%	-80.28%	-174.51%	-625.82%	-82.05%
Operating Margin	-83.46%	-75.87%	-132.15%	-135.79%	-70.53%	-1,162.13%	-133.37%	-118.08%	-168.46%	-578.65%	-59.09%
EBIT Margin	-83.92%	-71.97%	-81.69%	-134.68%	-68.40%	-1,627.64%	-130.57%	-95.28%	-179.16%	-651.55%	-85.72%
Profit (Net Income) Margin	-82.77%	-70.16%	-70.61%	-122.88%	-59.90%	-3,828.31%	-128.74%	-153.75%	-177.41%	598.48%	600.91%
Tax Burden Percent	100.24%	99.19%	100.40%	100.12%	100.44%	305.25%	110.83%	183.02%	105.43%	-99.73%	-869.44%
Interest Burden Percent	98.40%	98.28%	86.09%	91.13%	87.19%	77.05%	88.96%	88.17%	93.92%	92.11%	80.63%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-50.50%	-46.92%	0.00%	0.00%	0.00%	-1,606.74%	-62.31%	-182.23%	-252.70%	0.00%	-30.80%
ROIC Less NNEP Spread (ROIC-NNEP)	-43.82%	-40.61%	0.00%	0.00%	0.00%	-1,596.85%	-56.76%	-178.27%	-249.53%	0.00%	-65.44%
Return on Net Nonoperating Assets (RNNOA)	18.91%	15.74%	0.00%	0.00%	0.00%	1,365.08%	32.19%	149.04%	205.94%	0.00%	50.51%
Return on Equity (ROE)	-31.60%	-31.19%	0.00%	0.00%	0.00%	-241.66%	-30.13%	-33.19%	-46.77%	-16.72%	19.72%
Cash Return on Invested Capital (CROIC)	-33.41%	-30.36%	0.00%	0.00%	0.00%	0.00%	-267.05%	0.00%	0.00%	-1,233.82%	81.91%
Operating Return on Assets (OROA)	-23.40%	-21.46%	0.00%	0.00%	0.00%	-316.71%	-14.80%	-25.44%	-48.83%	-94.23%	-12.13%
Return on Assets (ROA)	-23.09%	-20.92%	0.00%	0.00%	0.00%	-744.93%	-14.59%	-41.05%	-48.36%	86.55%	85.06%
Return on Common Equity (ROCE)	14.36%	18.21%	0.00%	0.00%	0.00%	-123.19%	-30.13%	-33.19%	-46.77%	-16.72%	19.72%
Return on Equity Simple (ROE_SIMPLE)	57.49%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-15	-15	-42	-35	-22	-7.24	-19	-18	-23	-13	-8.75
NOPAT Margin	-58.42%	-53.11%	-92.51%	-95.05%	-49.37%	-813.49%	-93.36%	-82.66%	-117.92%	-405.05%	-41.37%
Net Nonoperating Expense Percent (NNEP)	-6.69%	-6.31%	0.00%	-4.97%	-2.52%	-9.89%	-5.55%	-3.96%	-3.17%	7.13%	34.65%
Return On Investment Capital (ROIC_SIMPLE)	-	17.71%	-	-	-	-1.53%	-4.15%	-4.23%	-5.76%	-3.07%	-1.56%
Cost of Revenue to Revenue	56.03%	52.42%	46.89%	59.93%	48.27%	302.81%	45.36%	51.16%	51.49%	16.51%	46.52%
SG&A Expenses to Revenue	87.88%	75.76%	103.08%	101.26%	76.50%	762.81%	147.48%	129.15%	136.02%	510.68%	87.99%
R&D to Revenue	25.11%	24.71%	35.09%	51.67%	29.26%	-149.66%	26.90%	28.59%	32.51%	64.59%	10.01%
Operating Expenses to Revenue	127.43%	123.45%	185.27%	175.86%	122.26%	959.33%	188.01%	166.92%	216.97%	662.14%	112.57%
Earnings before Interest and Taxes (EBIT)	-21	-20	-37	-50	-31	-14	-26	-21	-35	-21	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-17	-17	-35	-50	-29	-12	-23	-17	-34	-20	-17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	1.29	1.46	1.38	0.90	1.07	1.24	1.16	0.64
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	1.73	1.99	1.38	1.30	1.07	1.24	1.16	0.64
Price to Revenue (P/Rev)	2.18	1.65	6.20	0.00	0.00	7.16	6.23	2.70	2.98	5.77	4.16
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.59
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	21.81%
Enterprise Value to Invested Capital (EV/IC)	4.13	3.89	0.00	1.87	2.27	0.00	0.77	0.00	0.00	32.70	0.00
Enterprise Value to Revenue (EV/Rev)	4.53	4.09	0.00	0.00	0.00	3.94	2.31	1.30	1.70	3.27	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	8.50	0.00	2.50	2.93	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.36	0.39	0.00	0.11	0.11	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.33	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.43	-0.39	0.00	-0.59	-0.56	-0.85	-0.57	-0.84	-0.83	-1.01	-0.77
Leverage Ratio	1.76	1.82	0.00	1.50	1.53	1.47	1.28	1.35	1.37	1.32	1.20
Compound Leverage Factor	1.73	1.78	0.00	1.37	1.33	1.14	1.13	1.19	1.29	1.21	0.97
Debt to Total Capital	26.46%	28.01%	0.00%	9.74%	10.14%	0.06%	0.07%	0.07%	0.07%	0.07%	0.05%
Short-Term Debt to Total Capital	2.05%	26.26%	0.00%	9.69%	10.08%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	24.41%	1.76%	0.00%	0.05%	0.05%	0.06%	0.07%	0.07%	0.07%	0.07%	0.05%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	127.50%	137.29%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-53.96%	-65.30%	0.00%	90.26%	89.86%	99.94%	99.93%	99.93%	99.93%	99.93%	99.95%
Debt to EBITDA	-1.08	-1.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.08	0.84	0.00	0.00	0.00	2.99	2.99	1.87	1.56	2.18	5.73
Long-Term Debt to EBITDA	-1.00	-0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-1.21	-1.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	1.20	0.96	0.00	0.00	0.00	3.28	3.91	2.36	2.04	2.76	7.85
Long-Term Debt to NOPAT	-1.12	-0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-2.66	-3.37	0.00	0.00	0.00	0.75	-0.40	-0.01	-0.29	-0.29	1.22
Noncontrolling Interest Sharing Ratio	145.43%	158.40%	0.00%	0.00%	0.00%	49.02%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.30	1.45	0.00	3.88	3.76	5.70	6.12	5.16	4.38	4.19	12.36
Quick Ratio	2.81	1.23	0.00	3.45	3.33	4.67	5.22	2.57	1.93	1.86	11.18
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2.04	2.10	83	-85	-85	124	-216	170	178	-41	153
Operating Cash Flow to CapEx	-1,260.99%	-18,026.92%	-7,999.49%	0.00%	-1,235.88%	-415.70%	-599.19%	-1,095.28%	-2,505.87%	-250.00%	-8,174.91%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	79.87	0.00	0.00	217.21	0.00	18,888.68	17,805.04	-8,251.36	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	-60.48	0.00	0.00	-24.58	0.00	-2,296.44	-2,220.20	-238.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-61.24	0.00	0.00	-30.49	0.00	-2,506.11	-2,308.80	-333.20	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.28	0.30	0.00	0.00	0.00	0.19	0.11	0.27	0.27	0.14	0.14
Accounts Receivable Turnover	6.21	5.76	0.00	0.00	0.00	5.29	1.85	7.18	6.81	6.06	3.31
Inventory Turnover	2.60	2.66	0.00	0.00	0.00	2.23	0.81	2.66	2.62	2.10	1.43
Fixed Asset Turnover	4.11	4.27	0.00	0.00	0.00	3.88	1.51	5.18	5.31	4.06	2.84
Accounts Payable Turnover	6.85	6.52	0.00	0.00	0.00	6.46	2.88	8.93	10.14	8.18	4.39
Days Sales Outstanding (DSO)	58.74	63.40	0.00	0.00	0.00	68.99	197.14	50.82	53.57	60.25	110.27
Days Inventory Outstanding (DIO)	140.55	137.16	0.00	0.00	0.00	163.32	452.94	137.13	139.57	173.70	255.02
Days Payable Outstanding (DPO)	53.28	56.00	0.00	0.00	0.00	56.52	126.64	40.86	35.98	44.60	83.10
Cash Conversion Cycle (CCC)	146.01	144.56	0.00	0.00	0.00	175.78	523.44	147.09	157.17	189.36	282.19
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	115	112	0.00	171	178	-20	197	-17	-23	8.54	35
Invested Capital Turnover	0.86	0.88	0.00	0.00	0.00	1.98	0.67	2.20	2.14	-15.34	0.74
Increase / (Decrease) in Invested Capital	-13	-17	-125	50	63	-131	197	-188	-201	28	-162
Enterprise Value (EV)	476	435	0.00	319	405	359	152	219	283	279	-168
Market Capitalization	229	175	786	659	716	651	409	456	497	492	359
Book Value per Share	($1.67)	($1.86)	$0.00	$1.37	$1.32	$1.27	$1.20	$1.12	$1.05	$1.10	$1.44
Tangible Book Value per Share	($3.07)	($3.22)	$0.00	$1.02	$0.97	$1.27	$0.83	$1.12	$1.05	$1.10	$1.44
Total Capital	244	227	0.00	565	545	472	455	425	400	425	561
Total Debt	65	64	0.00	55	55	0.30	0.30	0.30	0.30	0.30	0.30
Total Long-Term Debt	60	3.98	0.00	0.30	0.30	0.30	0.30	0.30	0.30	0.30	0.30
Net Debt	-64	-51	0.00	-340	-311	-293	-258	-237	-214	-213	-526
Capital Expenditures (CapEx)	0.91	0.08	0.78	0.00	2.26	3.38	5.05	1.89	0.89	0.48	0.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-4.91	-6.48	0.00	16	22	17	30	171	170	158	24
Debt-free Net Working Capital (DFNWC)	124	108	0.00	411	388	310	288	408	364	346	479
Net Working Capital (NWC)	119	49	0.00	356	333	310	288	408	364	346	479
Net Nonoperating Expense (NNE)	6.18	4.81	-9.97	10	4.74	27	7.15	15	12	-32	-136
Net Nonoperating Obligations (NNO)	-64	-51	0.00	-340	-311	-491	-258	-442	-423	-416	-526
Total Depreciation and Amortization (D&A)	3.82	2.97	2.53	0.00	2.10	2.82	3.33	3.26	0.91	0.83	0.78
Debt-free, Cash-free Net Working Capital to Revenue	-4.67%	-6.09%	0.00%	0.00%	0.00%	18.80%	45.24%	101.17%	101.89%	185.61%	27.91%
Debt-free Net Working Capital to Revenue	117.84%	101.95%	0.00%	0.00%	0.00%	340.62%	438.09%	241.49%	219.00%	405.43%	555.62%
Net Working Capital to Revenue	113.09%	45.97%	0.00%	0.00%	0.00%	340.62%	438.09%	241.49%	219.00%	405.43%	555.62%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.27)	($0.24)	$0.00	($0.12)	($0.07)	($0.06)	($0.07)	($0.09)	($0.09)	$0.05	$0.33
Adjusted Weighted Average Basic Shares Outstanding	79.15M	79.16M	0.00	372.33M	371.54M	353.25M	378.23M	380.50M	382.63M	381.62M	388.20M
Adjusted Diluted Earnings per Share	($0.27)	($0.24)	$0.00	($0.12)	($0.07)	($0.06)	($0.07)	($0.09)	($0.09)	$0.05	$0.33
Adjusted Weighted Average Diluted Shares Outstanding	79.15M	79.16M	0.00	372.33M	371.54M	353.25M	378.23M	380.50M	382.63M	381.62M	388.20M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	79.40M	290.12M	0.00	371.15M	372.26M	378.99M	379.82M	382.00M	384.57M	390.07M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-12	-10	-27	-29	-17	-5.08	-17	-17	-16	-11	-6.59
Normalized NOPAT Margin	-48.31%	-37.02%	-59.54%	-79.00%	-37.82%	-571.17%	-83.82%	-76.23%	-84.02%	-344.24%	-31.17%
Pre Tax Income Margin	-82.58%	-70.73%	-70.33%	-122.73%	-59.64%	-1,254.16%	-116.16%	-84.01%	-168.27%	-600.12%	-69.11%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-36.01	0.00	0.00	-25.33	0.00	-2,303.78	-3,503.00	-4,198.60	0.00
NOPAT to Interest Expense	0.00	0.00	-40.78	0.00	0.00	-12.66	0.00	-1,998.66	-2,305.66	-2,610.16	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	-36.77	0.00	0.00	-31.24	0.00	-2,513.44	-3,591.60	-4,293.80	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	-41.54	0.00	0.00	-18.57	0.00	-2,208.32	-2,394.26	-2,705.36	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-7.66%	-7.25%	-15.56%	0.00%	0.00%	-29.15%	-22.17%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Standard BioTools’ latest quarter showed a sharp improvement in headline profitability, but the underlying operating business remains under pressure. In Q1 2026, the company reported net income of $127.1 million, but that was driven primarily by $141.7 million of discontinued operations income rather than from continuing operations. Core operations still posted a $14.6 million loss, and operating cash flow was negative. That means investors should view the quarter as a mix of real balance sheet strengthening and one-time accounting benefits rather than a clean turnaround in the core business.

Cash and liquidity improved materially. Cash & equivalents rose to $265.8 million in Q1 2026 from $129.4 million in Q3 2025, while short-term investments increased to $189.4 million.
Net cash increased strongly in the quarter. Standard BioTools generated a $144.6 million increase in cash and equivalents, helped by divestiture-related proceeds.
Total equity improved sharply. Shareholders’ equity rose to $561.1 million from $399.7 million in Q3 2025.
Debt remains modest. Long-term debt was only $299,000 at quarter-end, leaving the company with a light debt load.
Gross profit was positive. Q1 2026 revenue of $21.1 million generated $11.3 million in gross profit, showing the core product mix can still support positive gross margins.
The biggest profit boost came from discontinued operations. The quarter’s bottom-line gain was heavily influenced by $141.7 million from discontinued operations, so it does not reflect recurring operating strength.
Investing cash flow was boosted by asset sales. The company recorded $363.2 million in divestitures and $15.0 million in investment sales, which helped fund the larger cash position.
Inventory remained meaningful. Inventory was $18.6 million, which is manageable but worth watching for a company still working toward stable operating scale.
Operating revenue rebounded versus late 2025. Revenue improved from $3.2 million in Q4 2025 to $21.1 million in Q1 2026, though this is still well below historical levels from 2023-2024.
Core operations remained unprofitable. Continuing operations posted a $14.6 million loss in Q1 2026, and operating income was negative $12.5 million.
Operating cash flow was negative. Net cash from operating activities came in at $(46.6) million, indicating the business is still consuming cash in its day-to-day operations.
SG&A remains elevated relative to revenue. Selling, general and administrative expense was $18.6 million versus $21.1 million in revenue, leaving limited room for operating profitability.
Restructuring costs are still weighing on results. The company booked a $3.1 million restructuring charge in the quarter, suggesting the turnaround process is not yet complete.

Looking at the longer trend, the story is one of volatility with some recent stabilization. Revenue has fallen dramatically from 2023-2024 levels, while losses have been persistent. At the same time, Standard BioTools has built a sizable cash position and reduced debt, which gives it more flexibility. For retail investors, the key question is whether management can convert that liquidity into a durable operating improvement before cash burn and restructuring expenses erode the runway.

07/21/26 05:20 AM ETAI Generated. May Contain Errors.

Standard BioTools Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Standard BioTools' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Standard BioTools' net income appears to be on an upward trend, with a most recent value of -$74.90 million in 2025, rising from -$53.32 million in 2015. The previous period was -$138.89 million in 2024. See where experts think Standard BioTools is headed by visiting Standard BioTools' forecast page.

Standard BioTools' total operating income in 2025 was -$110.25 million, based on the following breakdown:

Total Gross Profit: $42.54 million
Total Operating Expenses: $152.79 million

Over the last 10 years, Standard BioTools' total revenue changed from $114.71 million in 2015 to $85.33 million in 2025, a change of -25.6%.

Standard BioTools' total liabilities were at $143.46 million at the end of 2025, a 2.0% increase from 2024, and a 43.8% decrease since 2015.

In the past 10 years, Standard BioTools' cash and equivalents has ranged from $21.66 million in 2019 to $166.73 million in 2024, and is currently $120.86 million as of their latest financial filing in 2025.

Over the last 10 years, Standard BioTools' book value per share changed from 3.99 in 2015 to 1.10 in 2025, a change of -72.4%.

Related Companies

Financial statements for NASDAQ:LAB last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Standard BioTools (LAB) Financials

Financials Breakdown Chart

Key Financial Trends

Standard BioTools Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Standard BioTools (LAB) Financials

Annual Income Statements for Standard BioTools

Quarterly Income Statements for Standard BioTools

Annual Cash Flow Statements for Standard BioTools

Quarterly Cash Flow Statements for Standard BioTools

Annual Balance Sheets for Standard BioTools

Quarterly Balance Sheets for Standard BioTools

Annual Metrics And Ratios for Standard BioTools

Quarterly Metrics And Ratios for Standard BioTools

Financials Breakdown Chart

Key Financial Trends

Standard BioTools Financials - Frequently Asked Questions

When does Standard BioTools' financial year end?

How has Standard BioTools' net income changed over the last 10 years?

What is Standard BioTools' operating income?

How has Standard BioTools' revenue changed over the last 10 years?

How much debt does Standard BioTools have?

How much cash does Standard BioTools have?

How has Standard BioTools' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools